Lannett’s Insulin Aspart Biosimilar Takes ‘Major Step’ Forward

Lannett’s Insulin Aspart On Track For Key Development Milestones After Positive Animal Study Results

Lannett and HEC’s insulin aspart biosimilar has performed well on an animal study in a boost to its strategic pipeline. Meanwhile, their insulin glargine faces delays.  

Laboratory worker writes on clipboard, with test-tube rack in the foreground
Lannett's Insulin Aspart Is A Major Pipeline Asset For the US Firm • Source: Shutterstock

New animal study results show that Lannett’s biosimilar insulin aspart candidate is “highly comparable” to Novo Nordisk’s US NovoLog, its reference biologic.

The pharmacokinetic study involved dosing animals with equal quantities of the drug via subcutaneous route.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business